356058-13-4

Usage

Uses

Used in Pharmaceutical Industry:
(6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIDIN-3-YL)METHANOL is used as a building block for the synthesis of pharmaceutical drugs due to its unique structure and potential pharmacological properties. Its trifluoromethyl group and pyridine ring make it an interesting target for further research and development in drug discovery and development.
Used in Drug Development:
(6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIDIN-3-YL)METHANOL is used for studying its biological activity and potential therapeutic uses. Its unique structure and potential pharmacological properties make it a valuable compound for exploring new treatment options in the field of drug development.

Upstream product

• 356058-14-5 6-(4-(trifluoromethyl)phenyl)nicotinaldehyde 
• 925-90-6 ethylmagnesium bromide 
• 21543-49-7 2-Chloro-5-hydroxymethylpyridine 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 356058-34-9 methyl 6-(4-(trifluoromethyl)phenyl)nicotinate 
• 73781-91-6 6-Chloronicotinic acid methyl ester 

Downstream Products

• 871250-60-1 3-{4-[6-(4-trifluoromethyl-phenyl)-pyridin-3-ylmethoxy]-benzoylamino}-propionic acid methyl ester 
• 851507-54-5 5-(chloromethyl)-2-(4-(trifluoromethyl)phenyl)pyridine 
• 356058-14-5 6-(4-(trifluoromethyl)phenyl)nicotinaldehyde 

Relevant academic research and scientific papers

HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF

Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.